Skip to content
Axcess News – Lifestyle
Author:
BridgeBio Pharma, Inc.
BridgeBio to Participate in September Investor Conferences
September 1, 2026
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
August 31, 2026
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
August 18, 2026
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 3, 2026
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
←
Previous Page
1
2
3
4
Next Page
→